Valuation: Prostatype Genomics AB

Market Cap 61.67M 6.04M 5.5M 5.07M 4.61M 8.65M 559M 9.09M 24.51M 305M 22.65M 22.17M 958M P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 57.9M 5.67M 5.16M 4.76M 4.33M 8.12M 525M 8.53M 23.01M 287M 21.27M 20.82M 900M EV / Sales 2024
327x
EV / Sales 2025 23.6x
Free-Float
84.84%
Yield 2024 *
-
Yield 2025 -
1 day-3.67%
1 week-6.11%
Current month-17.02%
1 month-13.40%
3 months-29.49%
6 months-76.53%
Current year-70.27%
1 week 0.07
Extreme 0.0702
0.1
1 month 0.07
Extreme 0.0702
0.11
Current year 0.07
Extreme 0.0702
2.28
1 year 0.07
Extreme 0.0702
2.28
3 years 0.07
Extreme 0.0702
240
5 years 0.07
Extreme 0.0702
11,800
10 years 0.07
Extreme 0.0702
18,400
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Director of Finance/CFO - 2023-10-30
General Counsel - 2023-02-28
Director TitleAgeSince
Chairman - 2016-12-31
Director/Board Member - 2017-12-31
Director/Board Member 74 2018-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-6.11%-84.13%-99.85% 6.04M
+1.00%-9.52%+3.60%+18.74% 103B
+3.31%-4.70%-3.14%+91.33% 99.34B
-5.70%-14.32%+18.54%+406.77% 39.64B
-0.77%-4.18%+9.46%+86.02% 31.77B
-0.47%-0.90%+38.21%+72.87% 29.81B
-0.31%-0.51%+35.05%+92.29% 28.42B
-0.15%-7.99%+37.11%+297.69% 20.95B
-1.97%-4.59%-17.36%-22.21% 19.39B
0.00%-0.38%-2.71%+33.67% 16.97B
Average -0.87%-5.17%+3.46%+97.73% 39B
Weighted average by Cap. +0.30%-6.24%+9.30%+105.30%

Financials

2024 2025
Net sales 199K 19.48K 17.74K 16.35K 14.87K 27.9K 1.8M 29.32K 79.09K 985K 73.1K 71.56K 3.09M 594K 58.15K 52.97K 48.81K 44.39K 83.29K 5.39M 87.53K 236K 2.94M 218K 214K 9.23M
Net income -41.05M -4.02M -3.66M -3.37M -3.07M -5.76M -372M -6.05M -16.32M -203M -15.08M -14.76M -638M -44.5M -4.36M -3.97M -3.66M -3.33M -6.24M -403M -6.56M -17.69M -220M -16.35M -16M -692M
Net Debt -9.35M -916K -834K -768K -699K -1.31M -84.79M -1.38M -3.72M -46.31M -3.44M -3.36M -145M -3.77M -369K -336K -310K -282K -528K -34.16M -555K -1.5M -18.66M -1.38M -1.35M -58.56M
Projected Income Statement - Annual - Prostatype Genomics AB
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
26-11-20 SEK 0.0892 -3.67% 1,083,923
26-11-19 SEK 0.0926 +3.35% 9,553,215
26-11-18 SEK 0.0896 -6.08% 2,093,145
26-11-17 SEK 0.0954 -0.42% 1,213,406
26-11-16 SEK 0.0958 +0.84% 1,364,732
  1. Stock Market
  2. Stocks
  3. PROGEN Stock